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BACKGROUND: DNA aneuploidy reflects gross genomic changes. It can be measured by flow cytometry (FCM-DNA) or image
cytometry (ICM-DNA). In gastric cancer, the prevalence of DNA aneuploidy has been reported to range from 27 to 100%, with
conflicting associations with clinicopathological variables. The aim of our study was to compare the DNA ploidy status measured
using FCM-DNA and ICM-DNA in gastric cancer and to evaluate its association with clinicopathological variables.
METHODS: Cell nuclei were isolated from 221 formalin-fixed, paraffin-embedded gastric cancer samples. DNA ploidy was assessed
using FCM-DNA and ICM-DNA.
RESULTS: A total of 178 (80.5%) gastric cancer samples were classified as DNA aneuploid using FCM-DNA, compared with 172
(77.8%) gastric cancer samples when using ICM-DNA. Results obtained from both methods were concordant in 183 (82.8%) cases
(k¼0.48). Patients with ICM-DNA diploid gastric cancer survived significantly longer than those with ICM-DNA aneuploid gastric
cancer (log rank 10.1, P¼0.001). For FCM-DNA data, this difference did not reach statistical significance. The multivariate Cox model
showed that ICM-DNA ploidy status predicted patient survival independently of tumour-node-metastasis status.
CONCLUSION: ICM-DNA ploidy status is an independent predictor of survival in gastric cancer patients and may therefore be a more
clinically relevant read out of gross genomic damage than FCM-DNA.
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Despite its declining incidence, gastric cancer remains the second
leading cause of cancer death worldwide, with a very poor
prognosis (Parkin et al, 2001). In the United Kingdom and the
Netherlands, it ranks fifth as a cause of cancer death, with 7980
(UK figure from 2005, data obtained from http://info.
cancerresearchuk.org/cancerstats/types/stomach/?a¼5441) and 2000
(NL figure from 2005, data collected from http://www.ikcnet.nl/
page.php?id¼1868&nav_id¼114) new patients diagnosed with
gastric cancer annually. A complete surgical resection of the
primary cancer and all potentially involved lymph nodes is the
only way to potentially cure the disease. However, o30% of
patients are diagnosed with the disease at a resectable stage in the
United Kingdom (data obtained from http://www.rcseng.ac.
uk/rcseng/content/publications/docs/national-audit-of-oesophago-
gastric-cancer-report-2008). At present, the pathological TNM
(tumour-node-metastasis) classification is considered as the ‘gold
standard’ for predicting patient survival after surgical resection
(Sobin and Wittekind, 1997; Klein et al, 2001). However, patients
with gastric cancers of similar TNM stage show a large variation in
survival. Therefore, it seems to be necessary to identify markers
that help to better characterise gastric cancer at a molecular level
and therefore, increase the precision of prognosis prediction for
individual patients.
A number of studies have been published investigating DNA
ploidy in gastric cancer, with contradicting results regarding the
relationship of DNA ploidy status and tumour stage or patient
survival (Brito et al, 1993; Suh and Min, 1993; Abad et al, 1998;
Baba et al, 2002; Grabsch et al, 2004), which is most likely because
of the small number of gastric cancers within studies and the
different technologies used.
The DNA ploidy status can be measured either using flow
cytometry (FCM-DNA) or image cytometry (ICM-DNA). The DNA
ploidy status measured using flow cytometry is relatively fast and
has a high measurement precision, allowing the identification of
small deviations in DNA content (i.e., DNA index) within a large
population of tumour cell nuclei, as usually up to 50000 cell nuclei
are assessed. As only nuclei in suspension are measured using
FCM-DNA, one of the main disadvantages is the lack of visual
control of the measured object and the related lack of option of
‘artefact rejection’, as the morphological information of the cell
nucleus cannot be assessed. In addition, relatively large amounts of
tissue are required to prepare the suspension of nuclei, and
repeating the measurement using the same suspension is
technically challenging. Moreover, low-frequency DNA abnormal-
ities may be missed as they can be obscured in the density profile
(Cornelisse and Van Driel-Kulker, 1985). The DNA ploidy status
measured using image cytometry overcomes some of these
disadvantages by allowing the visual control as well as the Received 20 February 2009; revised 25 June 2009; accepted 27 July 2009
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sselection of nuclei on the basis of morphologically or additionally
measured features, such as nuclear shape and texture. In addition,
ICM-DNA allows additional or repeat measurements, because the
specimen is a fixed and stained nuclear suspension deposited onto
a glass slide, which can be kept and stored indefinitely. The main
disadvantage of ICM-DNA is the lower throughput, that is, the
number of nuclei that can be measured in a given time, which
affects the number of cases that can be assessed per day.
The aim of this study was to determine the prognostic value of
DNA ploidy status in gastric cancer, measured by both FCM-DNA
and ICM-DNA, and to analyse the relationship of DNA ploidy
status with clinicopathological variables and patient survival.
MATERIALS AND METHODS
Patients
A total of 221 patients with primary gastric cancer, who underwent
gastrectomy with curative intent and D2 lymph node dissection at
the Academic Department of Surgery at the Leeds General
Infirmary (Leeds, UK) between 1970 and 2004, were included in
this study. None of the patients received neoadjuvant or adjuvant
systemic treatment or radiotherapy. The clinicopathological data
are summarised in Table 1. The study was approved by the Local
Research Ethics Committee (LREC No. CA01/122).
Tissue processing
Representative formalin-fixed, paraffin-embedded tissue blocks
were retrieved from the pathology archive of the Department of
Histopathology (Leeds General Infirmary). ‘Sandwich’ sections of
4-mm thickness were cut and stained with haematoxylin and eosin
to confirm the presence of gastric cancer. Nuclear suspensions
were prepared from 50-mm-thick sections according to the Hedley
procedure (Hedley et al, 1983). Part of the nuclear suspension was
stained with DAPI (40,6-diamidino-2-phenylindole, Partec Instru-
ments, Muenster, Germany) for FCM-DNA, and cytospins were
prepared from the other part by centrifugation of the specimen for
15min at 3000r.p.m. and staining using the Feulgen method
according to the consensus of the European Society for Analytical
Cellular Pathology (Haroske et al, 2001), with minor modifications.
In short, cytospin preparations were incubated with 5 N HCl for
30min at 271C, rinsed in distilled water for 5min, stained with
fresh Schiff’s reagents for 45min, and then washed in running tap
water for 15min. The cytospin slides were then dehydrated and
coverslipped.
Measurement of FCM-DNA
FCM-DNA measurements were determined within 3h after DAPI
staining with a Partec PAS II mercury lamp-based flow cytometer
(Partec Instruments), using trout erythrocytes as external control
cells. The procedure is described in detail elsewhere (Bergers et al,
1996).
Measurement of ICM-DNA
The DNA content of stained nuclei was measured and analysed by
ICM-DNA according to a published protocol (Rijken et al, 1999).
The guidelines of the consensus report of the European Society for
Analytical Cellular Pathology (Haroske et al, 2001) were followed.
Before every image analysis session, Ko ¨hler illumination was
applied, and the camera was switched on at least 15min before
measurement to ensure standardised conditions. Images were
linearly corrected for shading with two empty images, namely one
illuminated and one dark-current image (Tenkate et al, 1993). The
resulting corrected grey values provided a measure for the local
optical density. Segmentation was carried out in a fully automatic
manner on the basis of the algorithm described by Vossepoel et al
(1979), and a filter to remove debris and aggregates was active
during measurement.
If available, at least 2000 nuclei were measured in a fully
automatic manner, and lymphocytes and fibroblasts were included
as internal DNA diploid controls. Using classification algorithms,
ellipsoid objects resembling fibroblasts, and round dark condense
objects resembling lymphocytes, were automatically identified.
Table 1 Clinicopathological and univariate survival data of 221 patients with gastric cancer
All cases
n¼221 (%)
Survival
P-value
All cases
n¼221 (%)
Survival
P-value
Gender pT status
Male 142 (64) 0.49 pT1 14 (6) o0.001
Female 79 (36) pT2 86 (39)
pT3 110 (50)
Age pT4 11 (5)
Median (range) 71 (34–96)
pN status
Age categories (years) pN0 67 (30) o0.001
o50 12 (5) 0.15 pN1 96 (43)
50–70 80 (36) pN2 44 (20)
X70 129 (58) pN3 14 (6)
Tumour type pM status
Intestinal 147 (67) 0.54 pM0 201 (91) 0.07
Diffuse 44 (20) pM1 8 (4)
Mixed 30 (14) Missing 12 (5)
Tumour location Clinical stage
Cardia 43 (20) 0.04
a I 45 (20) o0.001
Body 53 (24) II 52 (24)
Antrum 93 (42) III 85 (39)
Whole stomach 5 (2) IV 27 (12)
Missing 27 (12) Missing 12 (5)
Significant correlations are in bold.
aThe whole stomach shows shorter survival than does the antrum, body, and cardia separately.
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calibrate and scale the DNA histogram. Another set of classifica-
tion algorithms was applied to automatically remove the majority
of remaining debris and aggregates from the data set. The resulting
DNA histograms were visually inspected and nuclei, which should
have been removed on the basis of features such as shape and
texture automatically, but were missed by the classification
algorithms, were removed manually. A median of 1024 high-
quality nuclei (range: 204–1744) was measured per case.
By convention in DNA cytometry, nuclear DNA content is
measured in relative units ‘c’, in which the DNA content of normal,
non-tumour nuclei is set at 2c. In this study, the 2c reference value
was determined by taking the mean DNA content measured for
nuclei that were identified as fibroblasts and lymphocytes. After
establishing the 2c reference value, the histogram was scaled up to
10c with a fixed number of 256 bins to obtain standardised
histograms that cover a wide range of c values that potentially
occur in populations of tumour nuclei.
Analysis of DNA histogram
All FCM-DNA and ICM-DNA histograms were analysed using the
MultiCycle AV computer programme (Phoenix Flow Systems, San
Diego, CA, USA), according to a previously described protocol
(Bergers et al, 1995).
The DNA index was calculated by dividing the modal channel
number of DNA aneuploid peaks by the corresponding number of
the DNA diploid peak. In case of only one cell cycle, the DNA
index was set at 1.00. On the basis of the DNA index, gastric
cancers measured using FCM-DNA were classified into three
subclasses on the basis of previously published guidelines
(Ormerod et al, 1998): DNA diploid (only one cell cycle present),
DNA tetraploid (1.9pDNA indexo2.1), and DNA aneuploid
(1oDNA indexo1.9 or DNA indexX2.1). Gastric cancers
measured using ICM-DNA were classified into three subclasses
on the basis of previously published guidelines (Haroske et al,
2001): DNA diploid (only one cell cycle present), DNA tetraploid
(1.8pDNA indexo2.2), and DNA aneuploid (1.1pDNA
indexo1.8 or DNA indexX2.2).
Gastric cancers measured using ICM-DNA were additionally
classified on the basis of the so-called 9c exceeding rate (9c ER)
(Haroske et al, 2001). The 9c ER is defined as the percentage of
cells exceeding a DNA content of 9c and has been previously used
for the grading of malignancy (Haroske et al, 2001). If a case
classified as DNA diploid or DNA tetraploid demonstrated a 9c ER
40, this case was reclassified as DNA aneuploid, as the presence of
tumour nuclei with DNA content exceeding 9c is believed to be
evidence of aneuploidy (Motherby et al, 2002). Using FCM-DNA
cytometry, by definition, the 9c ER cannot be determined, as this
requires a visual inspection of measured objects to exclude
clumping artefacts because of clumped nuclei that could give rise
to false calls.
Cases were classified according to four different category
definitions:
(a) Two ‘traditional’ categories as introduced by Hedley et al
(1993): (i) DNA diploid and (ii) DNA non-diploid (category
definition A; Table 2A)
(b) Three categories (i) DNA diploid, (ii) DNA tetraploid, and
(iii) DNA aneuploid (category definition B; Table 2B)
(c) Two categories: (i) DNA non-aneuploid (DNA diploid or DNA
tetraploid tumours) and (ii) DNA aneuploid tumours (cate-
gory definition C; Table 2C)
(d) Two categories: (i) DNA non-aneuploid (DNA diploid or
DNA tetraploid) with 9c exceeding the rate of zero and (ii)
DNA aneuploid or DNA non-aneuploid (DNA diploid or DNA
tetraploid) with 9c exceeding rate greater than zero (category
definition D; Table 2D). It should be noted that category D can
only be used with ICM-DNA data for reasons discussed above.
To still be able to evaluate any additional value of 9c ER (a key
feature of category D), we compared the outcome of category
definition D for ICM-DNA with category definition C for FCM-
DNA, as the 9c ER is the only difference between category
definitions C and D.
Statistical analysis
Statistical analyses were performed using SPSS (SPSS Version 15
Inc., Chicago, IL, USA). For discrete variables, the w
2 test was used,
or Fisher’s exact test if the expected count in a cell was less than
five. The correlation between FCM-DNA and ICM-DNA DNA
indexes was evaluated by linear regression analysis. Survival time
was measured in years from the time of surgery to death. Patients
who died of non-cancer-related causes or who were still alive at the
end of the study period were censored. Kaplan–Meier curves were
plotted and differences between curves were analysed with the
Mantel–Cox test. For univariate and multivariate analyses of the
predictive values of variables, the Cox proportional hazard model
was used, using enter and remove limits of 0.05 and 0.1. A linear
predictor score (LPS) was calculated from the Cox model. Results
from fitting a Cox model were presented as the regression
coefficient, B, the P-value of B in the Cox model, and the hazard
ratio, exp (B). The LPS for patients was calculated as PSi¼Bi
X1iþB2 X2iþyþBp Xpi for the variables 1 to p. Kaplan–Meier
curves of the population separated into a high-, intermediate-, and
low-risk tertile by the variable LPS illustrated the prognostic
values. P-values o0.05 were regarded as significant.
RESULTS
Clinicopathological characteristics
Tumour and patient characteristics are presented in Table 1.
A total of 142 (64%) patients were men and 79 (36%) were women.
The median age of all patients was 71 years, ranging from 34 to 96
years. The morphological tumour type of gastric cancers was
classified according to the Laure ´n classification (Lauren, 1965).
Median follow-up time was 21 months (range: 1.2–245.8 months).
Univariate analysis confirmed the pT status (Po0.001), pN status
(Po0.001), and clinical stage (Po0.001) as significant prognostic
factors (Table 1).
DNA ploidy results
DNA ploidy data were available from all 221 gastric cancer patients
for both, FCM-DNA and ICM-DNA (Table 2). The gastric cancers
were classified and compared using category definitions A (DNA
diploid vs DNA non-diploid), B (DNA diploid vs DNA tetraploid vs
DNA aneuploid), and C (DNA diploid or DNA tetraploid vs DNA
aneuploid) for both methods, FCM-DNA and ICM-DNA.
Category definition D (DNA diploid or DNA tetraploid and 9c
ER¼0 vs DNA aneuploid or DNA diploid or DNA tetraploid and
9c ER40), for reasons intrinsic to technology, can be used only for
ICM-DNA data and not for FCM-DNA data, as described in the
‘Materials and Methods’ section.
FCM-DNA results
On the basis of category definition A (Table 2A), 178 (81%) gastric
cancers were classified as DNA non-diploid and 43 (19%) as DNA
diploid. The frequency of DNA non-diploid gastric cancers was
higher in elderly patients (P¼0.02, data not shown) and in
patients with a higher number of positive lymph nodes (Table 3).
Category definition A did not yield any correlation of DNA ploidy
data with other clinicopathological variables, including patient
survival.
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(19%) patients with DNA diploid or 10 (5%) with DNA tetraploid
gastric cancer survived for a longer time compared with 168
(76%) patients with DNA non-diploid gastric cancer; however,
this difference was not significant (log rank of 5.5, P¼0.06).
Category definition B did not yield any correlation of DNA ploidy
data with other clinicopathological variables, including patient
survival.
On the basis of category definition C (Table 2C), 53 (24%)
patients with either DNA diploid or DNA tetraploid gastric cancer
survived significantly longer than did 168 (76%) patients with
DNA aneuploid gastric cancer (log rank: 5.3, P¼0.02, hazard ratio
1.8 (95% confidence interval: 1.1–2.9)). The results of the
univariate survival analysis of DNA ploidy status are shown in
Table 4. Category definition C did not yield any correlation of DNA
ploidy data with other clinicopathological variables, including
patient survival.
Category definition D is not applicable for FCM-DNA data (see
the ‘Materials and Methods’ section).
ICM-DNA results
On the basis of category definition A (Table 2A), 49 (22%) patients
with DNA diploid gastric cancers survived significantly longer
than did 172 (78%) patients with DNA non-diploid gastric cancers
(Table 4; log rank 10.1, P¼0.001, with hazard ratio of 2.3 (95%
confidence interval: 1.4–3.9)). In addition, a significant association
was found between DNA ploidy status and age (Po0.001, data not
shown), but not for any of the other clinicopathological factors
(Table 3).
On the basis of category definition B (Table 2B), 49 (22%)
patients with DNA diploid gastric cancer had a similar survival
compared with 17 (8%) patients with DNA tetraploid gastric
cancer, but they had a significantly longer survival compared with
155 (70%) patients with DNA aneuploid gastric cancer (log rank
13.8, P¼0.001, with hazard ratios of 1.0 (95% confidence interval:
0.3–3.1) for the DNA tetraploid category and 2.4 (95% confidence
interval: 1.4–4.2) for the DNA aneuploid category compared with
the DNA diploid category).
Table 2 Comparison of FCM-DNA and ICM-DNA for different DNA ploidy category definitions: (A) traditional DNA diploid vs DNA non-diploid
category; (B) DNA diploid vs DNA tetraploid vs DNA aneuploid; (C) DNA non-aneuploid (DNA diploid or DNA tetraploid) vs DNA aneuploid; (D) ICM-
DNA category i: (DNA diploid or DNA tetraploid) and 9c exceeding rate of 0 vs category ii: DNA aneuploid or ((DNA diploid or DNA tetraploid) and 9c
exceeding rate 40) vs FCM-DNA DNA non-aneuploid (DNA diploid or DNA tetraploid) vs DNA aneuploid; (E) Percentage of concordant results, P-value
obtained using either the w
2 or Fisher’s exact test and the k-values for Tables 2A–D
FCM-DNA
(A) Diploid Non-diploid Total
ICM-DNA
Diploid 27 (12.2%) 22 (10.0%) 49
Non-diploid 16 (7.2%) 156 (70.6%) 172
Total 43 178 221
FCM-DNA
(B) Diploid Tetraploid Aneuploid Total
ICM-DNA
Diploid 27 (12.2%) 1 (0.5%) 21 (9.5%) 49
Tetraploid 5 (2.3%) 3 (1.4%) 9 (4.1%) 17
Aneuploid 11 (5.0%) 6 (2.7%) 138 (62.4%) 155
Total 43 10 168 221
FCM-DNA
(C) Diploid+tetraploid Aneuploid Total
ICM-DNA
Diploid+tetraploid 36 (16.3%) 30 (13.6%) 66
Aneuploid 17 (7.7%) 138 (62.4%) 155
Total 53 168 221
FCM-DNA
(D) Diploid+tetraploid Aneuploid Total
ICM-DNA
Category 1 35 (15.8%) 26 (11.8%) 61
Category 2 18 (8.1%) 142 (64.3%) 160
Total 53 168 221
(E) Concordance (% cases) Pearson’s v
2 P-value j-value
Category definition
A 82.8 Po0.001 0.48
B7 6 P¼0.03* 0.43
C 78.7 Po0.001 0.46
D 80.1 Po0.001 0.48
Abbreviations: FCM-DNA, DNA ploidy status measured using flow cytometry; ICM-DNA, DNA ploidy status measured using image cytometry. *P-value obtained using Fisher’s
exact test.
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patients with either DNA diploid or DNA tetraploid gastric cancer
had a significantly longer survival compared with 155 (70%)
patients with DNA aneuploid gastric cancers (Table 4) (log rank
13.8, Po0.001, with hazard ratio of 2.4 (95% confidence interval:
1.5–4.0)).
A DNA diploid or DNA tetraploid ICM-DNA histogram, which
showed a 9c ER40, was reclassified as DNA aneuploid, (see the
‘Materials and Methods’ section: category definition D). None of
the ICM-DNA diploid but 5 of the 17 (29%) ICM-DNA tetraploid
gastric cancers had nuclei with 9c ER40. These five ICM-DNA
tetraploid gastric cancers were therefore reclassified as ICM-DNA
aneuploid. On the basis of category definition D (Table 2D), 61
(28%) patients with a DNA diploid or DNA tetraploid gastric
cancer had a significantly longer survival compared with 160
(72%) patients with DNA aneuploid gastric cancers (Table 4 and
Figure 1) (log rank of 16.8, Po0.001, with hazard ratio of 2.8 (95%
confidence interval: 1.7–4.7).
FCM-DNA and ICM-DNA comparison
A significant correlation was observed between the FCM-DNA and
ICM-DNA DNA indeces for all DNA ploidy category definitions
(Po0.001, r¼0.61).
When comparing DNA diploid with DNA aneuploid gastric
cancers (category definition A), results from both methods were
concordant in 183 (83%) gastric cancers (w
2 Po0.001, k¼0.48;
Table 2A and E). In all, 16 (37%) gastric cancers were classified as
DNA diploid by FCM-DNA, but as DNA aneuploid by ICM-DNA,
and 22 (45%) gastric cancers were classified as DNA diploid by
ICM-DNA, but as DNA aneuploid by FCM-DNA.
Using ICM-DNA, the number of DNA tetraploid gastric cancers
was higher compared with FCM-DNA (17 and 10 gastric cancers,
respectively). When comparing DNA diploid vs DNA tetraploid vs
DNA aneuploid (category definition B), results from both methods
were concordant in 168 (76%) gastric cancers (Fisher’s exact test:
P¼0.03, k¼0.43; Table 2B and E). Interestingly, only three of
Table 3 Clinicopathological data and associations with DNA ploidy data
All cases
FCM-DNA
diploid
FCM-DNA
non-diploid Pearson’s v
2
ICM-DNA
diploid
ICM-DNA
non-diploid Pearson’s v
2
n¼221 (%) n¼43 (%) n¼178 (%) P-value n¼49 (%) n¼172 (%) P-value
Tumour type
Intestinal 147 (67) 28 (19) 119 (81) 0.45 32 (22) 115 (78) 0.08
Diffuse 44 (20) 11 (25) 33 (75) 14 (32) 30 (68)
Mixed 30 (14) 4 (13) 26 (87) 3 (10) 27 (90)
pT status
pT1 14 (6.3%) 4 (29) 10 (71) 0.72 3 (21) 11 (79) 0.99
pT2 86 (38.9%) 16 (19) 70 (81) 19 (22) 67 (78)
pT3 110 (49.8%) 20 (18) 90 (82) 25 (23) 85 (77)
pT4 11 (5.0%) 3 (27) 8 (73) 2 (18) 9 (82)
pN status
pN0 67 (30.3%) 18 (27) 49 (73) 0.009 17 (25) 50 (75) 0.28
pN1 96 (43.4%) 22 (23) 74 (77) 24 (25) 72 (75)
pN2 44 (19.9%) 1 (2) 43 (98) 5 (11) 39 (89)
pN3 14 (6.3%) 2 (14) 12 (86) 3 (21) 11 (79)
Clinical stage
I 9 (4.1%) 8 (18) 37 (82) 0.11 7 (16) 38 (84) 0.23
II 52 (23.5%) 14 (27) 38 (73) 15 (29) 37 (71)
III 53 (24.0%) 10 (12) 75 (88) 13 (15) 72 (85)
IV 27 (12.2%) 3 (11) 24 (89) 5 (19) 22 (82)
Missing 12 (5.4%) 8 4 9 3
Abbreviations: FCM-DNA, DNA ploidy status measured using flow cytometry; ICM-DNA, DNA ploidy status measured using image cytometry. Significant associations in bold.
Table 4 Univariate survival analyses of FCM-DNA and ICM-DNA for different DNA ploidy category definitions
FCM-DNA ICM-DNA
Category
definition
Log rank
value P-value
Hazard ratio
(95% confidence interval)
a
Log-rank
value P-value
Hazard ratio
(95% confidence interval)
a
A 2.9 0.09 10.1 0.001 2.3 (1.4–3.9)
B 5.5 0.06 13.8 0.001 1.0 (0.3–3.1)
2.4 (1.4–4.2)
C 5.3 0.02 1.8 (1.1–2.9) 13.8 o0.001 2.4 (1.5–4.0)
D NA 16.8 o0.001 2.8 (1.7–4.7)
Abbreviations: FCM-DNA, DNA ploidy status measured using flow cytometry; ICM-DNA, DNA ploidy status measured using image cytometry; NA, not applicable. Same
category definitions as in Table 2. The column hazard ratios of category definition B shows two values. The first value is the hazard ratio of the DNA tetraploid category
compared with the DNA diploid nearest ratio category, and the second value is the hazard ratio of the DNA aneuploid category compared with the DNA diploid category.
aHazard ratio is only presented when significant (confidence interval does not contain 1), and represents values to reference group (i.e., favourable outcome).
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methods.
When comparing DNA tetraploid gastric cancers combined with
DNA diploid gastric cancers with DNA aneuploid gastric cancers
(category definition C), results from both methods were con-
cordant in 174 (78.7%) gastric cancers (w
2 Po0.001, k¼0.46;
Table 2C and E).
As the classification of DNA ploidy into category definition D
does not apply to FCM-DNA, we cannot directly compare ICM-
DNA category definition D with a similar FCM-DNA category
definition. However, to investigate the potential additional value of
recognising 9c ER within gastric cancers studied by ICM-DNA, we
compared the results from category definition D from ICM-DNA
with those from category definition C from FCM-DNA. When
comparing ICM-DNA category definition D (ICM-DNA DNA
diploid and DNA tetraploid gastric cancers that have a 9c ER40
(0 and 5 cases, respectively) combined with the DNA aneuploid
category vs ICM-DNA DNA diploid and DNA tetraploid gastric
cancers that do not have a 9c ER40) with FCM-DNA category
definition C (DNA tetraploid gastric cancers combined with
DNA diploid gastric cancers vs DNA aneuploid gastric cancers),
the results were concordant in 177 (80.1%) gastric cancers
(w
2 Po0.001, k¼0.48; Table 2D and E).
Multivariate overall survival
Multivariate analyses using statistically significant variables from
univariate analyses (Table 1) and the FCM-DNA-based ploidy
category definitions (category definitions A, B, and C, Table 2)
showed that lymph node status (pN) was the strongest prognostic
factor, followed by stage. No other factors including FCM-DNA
variables had a significant contribution.
Multivariate analyses using ICM-DNA variables showed that
lymph node status (pN), clinical stage, and ICM-DNA ploidy status
(using category definition D, Table 2D) were prognostically
significant. When dividing the study population in tertiles on the
basis of the linear prognostic score, the log rank was 52.8 with
Po0.001. Hazard ratios for the most favourable group of patients
with respect to survival as reference were 3.2 (95% confidence
interval: 1.6–6.2) and 8.1 (95% confidence interval: 4.2–15.9),
respectively.
DISCUSSION
Aneuploidy or gross genomic instability is a well-established
biological feature of many solid tumours (Lengauer et al, 1998;
Grabsch et al, 2004). At the nuclear level, this gross genomic
damage is reflected by abnormal DNA content, for example, DNA
aneuploidy, and can be measured using FCM-DNA and ICM-DNA
(Friedlander et al, 1984; Cornelisse and Van Driel-Kulker, 1985;
Mellin, 1990; Ormerod et al, 1998; Haroske et al, 2001). A wide
range of prevalence of DNA aneuploidy has been reported in
gastric cancer in the past, and no consensus has been reached
regarding the relationship between DNA ploidy status and
clinicopathological variables, including patient survival (Grabsch
et al, 2004). The majority of investigations on the prognostic value
of DNA ploidy in gastric cancers have been performed by FCM-
DNA (Grabsch et al, 2004; Yasa et al, 2005; Nesi et al, 2007; Doak,
2008) and, to our knowledge, only a single study has used both
methods, FCM-DNA and ICM-DNA, in parallel in gastric cancer
(Brito et al, 1994).
This study aimed at determining whether DNA ploidy status can
predict patient prognosis in a large retrospective series of gastric
cancer and whether there is a significant difference in DNA ploidy
status when measured using available cytometry methods.
FCM-DNA and ICM-DNA are both objective methods to study
abnormalities of nuclear DNA content. However, because
researchers used different methods to prepare nuclear suspensions
and to interpret histograms, published results are difficult to
compare, especially with regard to older studies (Brito et al, 1994;
Grabsch et al, 2004; Yasa et al, 2005; Nesi et al, 2007; Doak, 2008).
Lack of standardisation may, at least partially, explain why the
published prevalence of DNA aneuploidy in gastric cancer varies
so widely (27–100%). To overcome these difficulties, we followed
the guidelines of the European consensus report on standardisa-
tion of diagnostic DNA image cytometry (Haroske et al, 2001) and
DNA flow cytometry (Ormerod et al, 1998).
Our study demonstrated that FCM-DNA and ICM-DNA were
equally sensitive in detecting DNA non-diploid gastric cancers,
with the highest overall concordance of 83% of gastric cancers
when using the classification system introduced by Hedley et al
(1993) (‘category definition A’ in this study). The two alternative
DNA ploidy classification systems (category definitions B and C)
investigated in this study also showed concordance, but at a lower
level. The use of the 9c ER to classify gastric cancers as ICM-DNA
aneuploid (category definition D) did not increase the percentage
of concordant cases between the two methods above the
concordance achieved using Hedley’s classification.
In the past, only one study (Brito et al, 1994) has used both
methods in a small group of gastric cancers (n¼48). Unfortu-
nately, this study does not provide any information regarding the
concordance of results using ICM and FCM. The results of this
study are comparable with those of previous studies comparing
FCM-DNA and ICM-DNA in patients with breast cancer (Ellison
et al, 1995), in which 75% concordant cases were reported.
However, a higher concordance of 91% has been reported in a
small number of other cancers (Chen et al, 1995).
We can exclude intra-tumour heterogeneity as a possible factor
to explain the differences in DNA ploidy classification between
FCM and ICM, as FCM-DNA and ICM-DNA analyses were
performed using an aliquot from the same nuclear suspension.
Problems related to different preparation procedures and
differences in the interpretation of DNA histograms could
potentially explain the discrepancies between the FCM-DNA and
ICM-DNA classification found in our study. For example, DNA
non-diploid peaks detectable by ICM-DNA may not be visible in
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Figure 1 Overall survival related Kaplan–Meier survival curves of
patients stratified by DNA ploidy status ICM-DNA diploidþtetraploid
(n¼61) and ICM-DNA aneuploid (n¼160) gastric cancers taking into
account 9c exceeding rate. Log rank: 16.9, Po0.001, Hazard ratio: 2.8 (95%
confidence interval: 1.7–4.7).
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sFCM-DNA if large numbers of non-tumour DNA diploid nuclei
such as those derived from stromal and inflammatory cells are
present in the sample at the same time. False DNA tetraploid or
aneuploid peaks may be detected by FCM-DNA because of
clumping of nuclei, whereas ICM-DNA allows excluding nuclei
clumps during the visual inspection step of nuclei galleries (for
examples, see Figure 2). DNA non-diploid peaks detected by
FCM-DNA, but not by ICM-DNA, could be related to the fact that
non-diploid nuclei are more fragile (i.e., they are larger and
heavier) and may be more commonly destroyed than DNA diploid
nuclei during the centrifugation process in the preparation of
cytospin. Although the resolution of ICM-DNA histograms is still
slightly lower than that of DNA histograms obtained by FCM-
DNA, because of the lower number of nuclei that are measured in
ICM-DNA analyses, the resolution in our study has been improved
by measuring at least 2000 nuclei compared with measuring
typically between 100 and 400 nuclei in the past (Brito et al, 1994).
Besides the in-depth study comparing FCM-DNA and ICM-
DNA, this study demonstrated that ICM-DNA ploidy status, but
not FCM-DNA ploidy status, differs significantly between gastric
cancers with different morphology and with different TNM stages,
and can stratify patients into different prognostic groups. This is in
concordance with some, but not all, previously published studies
(Brito et al, 1994; Grabsch et al, 2004).
In summary, this study showed that patients with DNA non-
diploid gastric cancers measured by ICM-DNA have an unfavour-
able prognosis compared with patients with DNA diploid tumours.
Our study demonstrated that ICM-DNA-based DNA ploidy status
outperformed FCM-DNA-based DNA ploidy studies in predicting
survival in gastric cancer patients. Finally, our results suggest that
ICM-DNA DNA ploidy status, taking into account the 9c ER, has
an additional value to lymph node status and to clinical stage in
predicting the prognosis of gastric cancer patients. Further studies
are warranted to investigate whether ICM-DNA ploidy status can
be reliably measured in pre-treatment endoscopic biopsies and can
potentially been used to stratify patients for treatment.
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